VIP (6mg)

$71.00

VIP (6mg) is offered by Biotech Peptides for laboratory and analytical research. Vasoactive intestinal peptide is a 28-amino-acid neuropeptide that has been studied in relation to VPAC1, VPAC2, and PAC1 receptor signaling.pmc.ncbi.nlm.nih+1

  • Product: Vasoactive intestinal peptide

  • Common abbreviation: VIP

  • Listed quantity: 6 mg

  • Reference sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH₂

  • Intended use: Laboratory and analytical research only

Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.

For research use only. Not for human consumption.

SKU: VIP-6mg Category:
Description

VIP (6mg) for Laboratory Research

VIP (6mg) is offered by Biotech Peptides for laboratories investigating neuropeptide receptor signaling, immune-cell responses, and vascular biology. Vasoactive intestinal peptide, commonly abbreviated VIP, is a 28-amino-acid peptide that binds VPAC1 and VPAC2 receptors and can also interact with PAC1.pmc.ncbi.nlm.nih+1

For laboratories looking to buy VIP, this listing identifies a 6 mg quantity. Confirm the supplied material’s sequence, terminal groups, chemical form, and analytical characteristics against the requirements of the intended work.

Explore our research peptides for sale to review other laboratory-use listings.

VIP Product Information

Property Listing information
Product name Vasoactive intestinal peptide
Common abbreviation VIP
Listed quantity 6 mg
Intended application Laboratory and analytical research
Documentation inquiries Include the product name and batch or lot number, where available

The 6 mg designation describes the quantity stated for this listing. It does not independently establish net peptide content or confirm that a particular quantity-assay method has been performed.

VIP Reference Molecular Characteristics

The following characteristics describe the unmodified human VIP reference structure. They are not analytical confirmation of an individual commercial batch.

Reference characteristic Information
Peptide length 28 amino acids
Amino-acid sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂
One-letter sequence HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH₂
C-terminal group Amide
Molecular formula C₁₄₇H₂₃₇N₄₃O₄₃S
Approximate molecular weight 3,326.8 g/mol
PubChem compound identifier 16132300

The sequence, molecular formula, molecular weight, and C-terminal amidation are documented in the VIP reference record. Confirm the supplied chemical form and any counterions against manufacturer specifications before using reference values in analytical calculations.learntopeptide

VIP and Receptor Signaling Research

VIP primarily signals through VPAC1 and VPAC2, two class B G protein-coupled receptors. These receptors also bind pituitary adenylate cyclase-activating polypeptide, or PACAP. PAC1 is primarily a PACAP-preferring receptor and has lower affinity for VIP.pubmed.ncbi.nlm.nih+1

Activation of VPAC1 and VPAC2 is principally associated with Gs coupling, adenylyl cyclase activation, and increased intracellular cyclic AMP. Additional signaling through phospholipase C, calcium signaling, ERK, Akt, and CREB has also been described in receptor-specific contexts.pmc.ncbi.nlm.nih+1

Read the review of VIP and PACAP receptor signaling for the molecular mechanisms and receptor distinctions.

Pulmonary Vascular Research

Research in VIP-deficient mice has reported spontaneous pulmonary hypertension, pulmonary vascular remodeling, and lung inflammation. Gene-expression analysis in these animals identified altered expression of genes associated with vascular smooth-muscle proliferation, antiproliferative signaling, and inflammation.

A related study reported that VIP inhibited NFAT nuclear translocation in primary human pulmonary artery smooth-muscle cells and described VIP as an endogenous inhibitor of NFATc3 activity. The investigators interpreted this as a potential mechanism relevant to pulmonary vascular remodeling and inflammation.pubmed.ncbi.nlm.nih+1

These findings describe experimental animal and cell models. They do not establish that VIP treats pulmonary hypertension, pulmonary fibrosis, asthma, or any other respiratory condition in humans.

Read the primary study of VIP-deficient mice for the model and findings.

Immune-Cell Research

VIP has been studied in relation to dendritic cells, T-cell polarization, regulatory T cells, and cytokine signaling. Reviews describe VIP as capable of influencing immune responses through VPAC receptors expressed on immune cells.

The direction and magnitude of these effects depend on the cell type, activation state, receptor expression, and experimental conditions. An observation involving dendritic cells or a particular cytokine pathway does not establish that VIP suppresses inflammation, improves immune tolerance, or prevents transplant rejection in humans.pmc.ncbi.nlm.nih+1

Neurobiology Research

VIP has been studied as a neuropeptide with roles in synaptic transmission and neuronal signaling. A study of hippocampal CA1 pyramidal cells reported that VIP enhanced synaptic transmission through VPAC1 and VPAC2 receptor activation.

Research discussing neuroprotection, microglial activity, amyloid-beta clearance, or neurotrophic factors should be treated as model-specific. Such findings do not establish that VIP treats neurodegenerative disease, protects the brain, or improves cognition in humans.pmc.ncbi.nlm.nih+1

Research Limitations

Published VIP research examines receptor signaling, vascular biology, immune-cell function, and experimental disease models. It does not establish that VIP treats inflammatory bowel disease, pulmonary fibrosis, pulmonary hypertension, neurodegenerative disease, cardiac fibrosis, or any other condition.pubmed.ncbi.nlm.nih+2

Published research also does not verify the identity, purity, quantity, or biological activity of the commercial batch supplied with this listing.

Documentation and Batch Verification

Before selecting VIP (6mg), review the information associated with the exact material being supplied. Depending on your protocol, relevant documentation may include:

  • Product name and batch or lot identifier.

  • Manufacturer specifications and chemical form.

  • Complete sequence and terminal-group information.

  • Counterion information, where applicable.

  • Identity-testing methods and reported results.

  • Purity-testing methods and supporting analytical data.

  • Quantity or peptide-content measurements, where required.

  • Product-specific storage and handling instructions.

Match identifiers across the label, specifications, and analytical reports. Obtain clarification if the documentation uses inconsistent names, sequences, or molecular values.

For inquiries, provide “VIP (6mg),” the batch number where available, and the specific information your laboratory requires.

Storage and Handling

Follow the product-specific instructions supplied with the material and your laboratory’s applicable procedures.

Do not transfer storage temperatures, shelf-life claims, or preparation instructions from another supplier’s formulation or a modified VIP analogue. Obtain clarification if documented instructions are unavailable or unclear.

Frequently Asked Questions About VIP (6mg)

What is VIP?

VIP is vasoactive intestinal peptide, a 28-amino-acid neuropeptide. It has been studied in relation to VPAC1, VPAC2, and PAC1 receptor signaling.pmc.ncbi.nlm.nih+1

Is VIP the same as PACAP?

No. VIP and PACAP are related neuropeptides that share VPAC1 and VPAC2 receptors, but PAC1 is primarily a PACAP-preferring receptor.pubmed.ncbi.nlm.nih+1

Does VIP always reduce inflammation?

No. VIP has been studied as an immune modulator, but its effects depend on the cell type, receptor expression, activation state, and experimental conditions.pmc.ncbi.nlm.nih+1

What does the 6mg designation mean?

It is the quantity stated for this listing. It does not describe a concentration or independently establish net peptide content.

Does published research verify this product?

No. Publications describe the materials and conditions used by the investigators. Assess a commercial batch using relevant manufacturer specifications and analytical evidence.

Where can I find delivery information?

Review our shipping information for current order-processing and delivery terms.

Research Use Only

VIP (6mg) is sold for laboratory and analytical research only. Not for human or animal consumption, personal administration, medical treatment, diagnosis, or veterinary application.

Review our Research-Use-Only Policy before ordering.

Additional information
BrandBiotech Peptides
Shipping & Delivery